newsfilter
← Latest News
Business Wire·

Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress

Core royalty platform maintained strong performance, generating $61.3 million in revenue Innoviva Specialty Therapeutics achieved U.S. net product sales of $26.4 million for the first quarter, reflecting 52%